Dr. med. Dirk Manski

 You are here: Urology Textbook > Drugs in Urology > Co-trimoxazole


Review literature: (Simon and Stille, 1997).

Co-trimoxazole is an antibiotic with a fixed combination of trimethoprim (dihydrofolate reductase inhibitor) and sulfamethoxazole (sulfonamide).

Mechanism of Action of Co-trimoxazole

Co-trimoxazole is bactericidal due to the double inhibition of bacterial folic acid synthesis.

Antibiotic Spectrum of Co-trimoxazole:

Bacteria causing urinary tract infection such as E. coli, Enterococci, Mycoplasma, Klebsiella, Serratia, Enterobacter (KES group), but with increasing resistance rates.

Urologic Indications for Co-trimoxazole:

Treatment or prevention of urinary tract infection.

Pharmacokinetics of Co-trimoxazole

Side Effects of Co-trimoxazole


Skin rash, rarely severe skin reactions (Stevens-Johnson and Lyell syndrome).


Exacerbation of renal failure (reversible).


Bone marrow depression in case of long-term therapy, rarely agranulocytosis.

Drug Interactions with Co-trimoxazole

Co-trimoxazole enhances the effect of phenytoin and sulfonylureas. Increased toxicity of cyclosporine, barbiturates, p-aminosalicylic acid and methotrexate.

Contraindications of Co-trimoxazole

Dosage of Co-trimoxazole

The ratio between trimethoprim and sulfamethoxazole is 1:5. The dosage for adults is 480 mg (80 mg trimethoprim and 400 mg sulfamethoxazole) 1-0-1 p.o. to 960 mg p.o. 1-0-1. The dosage for children is 24 mg/kg p.o. co-trimoxazole 1-0-1.

In uncomplicated acute cystitis of women, co-trimoxazole is given for 3 days. In any other urinary tract infection, the recommended treatment duration is at least 7 days.

Index: 1–9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z


Simon und Stille 1997 SIMON, C. ; STILLE, W.:
Antibiotika-Therapie in Klinik und Praxis.
9. Auflage.
Stuttgart New York : Schattauer, 1997

  Deutsche Version: Cotrimoxazol